According to the latest data from the national bureau of statistics on June 6, the main business revenue of the pharmaceutical manufacturing industry was 912.3 billion yuan in the january-april period, up 11.2 percent year on year. Net profit was 97.6 billion yuan, up 14.5 percent year on year. In the context of increased financial support for medical institutions, medical institutions have eased the pressure on drug companies, and the pharmaceutical manufacturing industry has been more beautiful. 

 

Basically pass the "cold winter" 

 

According to statistics released by the national bureau of statistics, the medical industry has been largely through the winter, returning to double-digit growth. Meanwhile, net income grew faster than revenue growth. 

 

In fact, net profit growth for a-share pharmaceutical companies has generally been growing faster than revenue growth since mid-2016. Industry insiders expect the trend to continue in the next two to three years. 

 

"In recent years, the fiscal spending by the support in the field of medical demand side to support the supply side, gradually increase the financial subsidies to the medical institutions, medical institutions for medical enterprises bidding interacting, strength relief, pharmaceutical enterprise's profit margin improved." Tian tian, a medical researcher at citic securities, said. 

 

In the first three months of 2017, fiscal health expenditure reached 410.6 billion yuan, up 29.4 percent year on year, according to the ministry of finance. Health expenditure accounted for 8.94 per cent of total expenditures, up 1.94 per cent from 2016. On the budget side, the national health expenditure budget for 2017 is 1.4 trillion yuan, up 5.1 percent year on year, accounting for 7.2 percent of the country's fiscal expenditures. 

 

Resource integration accelerated 

 

Tian added that from the present situation, the industrial resources are converging to the leading enterprises. The pharmaceutical industry, consistency evaluation to accelerate the industry reshuffle, accessories industry faces of quality and technical upgrading, health insurance directory adjustment and negotiation mechanism will speed up product's capacity; In the field of medical distribution, the integration of business channels has started, and the "two-ticket" landing will accelerate the integration of resources. In the retail field of medicine, the concentration of the leading enterprises is increasing. 

 

Health care costs have increased year after year in 2009, and the golden age of health care for the medical industry has passed. Accounted for in the past two years, pharmaceutical industry facing hospital medicine reducing, flight check to strengthen, drug prices for medicine and ancillary drugs, antibiotics, including large infusion strengthening restrictions such as factors. 

 

National food drug safety administration of the southern medical relevant person in charge of economic research institute, told China securities journal reporter, 2017 pharmaceutical manufacturing growth is estimated at about 12%, the output value of 3.5 trillion yuan. That means the pharmaceutical market is adding about 300 billion new markets a year. 

 

Xu zhibiao, a fund manager at the bank for agriculture and silver, thinks that the current market for secondary market medicine is more cost-effective, and that "the bottom of the industry is over".